Elo Mutual Pension Insurance Co Takes $829,000 Position in Haemonetics Corporation $HAE

Elo Mutual Pension Insurance Co bought a new stake in Haemonetics Corporation (NYSE:HAE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,005 shares of the medical instruments supplier’s stock, valued at approximately $829,000.

Several other large investors have also recently bought and sold shares of the stock. William Blair Investment Management LLC grew its stake in Haemonetics by 13.7% in the third quarter. William Blair Investment Management LLC now owns 476,710 shares of the medical instruments supplier’s stock valued at $23,235,000 after purchasing an additional 57,332 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Haemonetics during the 3rd quarter worth approximately $1,358,000. Cary Street Partners Financial LLC raised its stake in shares of Haemonetics by 41.4% during the 3rd quarter. Cary Street Partners Financial LLC now owns 25,629 shares of the medical instruments supplier’s stock worth $1,249,000 after purchasing an additional 7,510 shares in the last quarter. Clark Estates Inc. NY acquired a new stake in shares of Haemonetics in the 3rd quarter valued at approximately $2,242,000. Finally, Isthmus Partners LLC boosted its holdings in shares of Haemonetics by 36.5% in the 3rd quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock valued at $3,007,000 after buying an additional 16,505 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HAE has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Barrington Research set a $94.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Robert W. Baird set a $81.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Stock Down 0.0%

HAE opened at $64.20 on Friday. The stock’s fifty day simple moving average is $68.56 and its 200 day simple moving average is $64.43. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The stock has a market cap of $2.98 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 1.34 and a beta of 0.28. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.